Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$57.04

0.735 (1.31%)

09:59
08/08/17
08/08
09:59
08/08/17
09:59

Bristol-Myers stock could be worth $64-$74 per share, says Goldman Sachs

Goldman Sachs analyst Jami Rubin believes that Bristol-Myers could be worth $64-$74 per share ,depending on the outcome of a trial of its CM-227 cancer treatment. The analyst notes that if the trial is successful, the company will have the only IO treatment that works in conjunction with the CTLA-4 protein receptor, and Rubin says this will be "particularly meaningful"if patients taking CM-227 show.a higher overall survival rate than those taking chom combos. Rubin thinks the stock could be worth $59-$75 per share in a takeover with no value for CM-227, and the analyst says that at $50 per share the stock is reflecting no value for the company's first line NSCLC treatment. Rubin keeps the stock on the Americas Buy List.

  • 11

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

BMY Bristol-Myers
$57.04

0.735 (1.31%)

07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
07/31/17
JANY
07/31/17
NO CHANGE
Target $107
JANY
Buy
Clovis partnership undercuts takeover thesis, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay says Clovis Oncology's (CLVS) clinical partnership with Bristol-Myer Squibb (BMY) undercuts his takeout thesis. The recent agreements across the PARP drugs implies no near-term takeovers, Chattopadhyay tells investors in a research note. He believes this will "likely to be disappointing to many." The analyst has a Buy rating on Clovis with a $107 price target. The shares in early trading are down $8.04, or 8% to $89.97.
07/31/17
LEER
07/31/17
NO CHANGE
LEER
Outperform
Clovis weakness unwarranted after Bristol-Myers pact, says Leerink
Leerink analyst Michael Schmidt thinks today's weakness in Clovis (CLVS) is unwarranted following the company's clinical collaboration agreement with Bristol-Myers (BMY) and presents a buying opportunity. This deal does not preclude a future acquisition of the company, but it does increase the competitiveness and value of Rubraca, argues Schmidt, who reiterates his Outperform rating on Clovis shares.

TODAY'S FREE FLY STORIES

ES

Eversource

$55.59

0.505 (0.92%)

, CTWS

Connecticut Water

$66.09

0.34 (0.52%)

14:23
06/19/18
06/19
14:23
06/19/18
14:23
Hot Stocks
Eversource reiterates Connecticut Water proposal, urges holders vote against SJW »

Eversource Energy (ES)…

ES

Eversource

$55.59

0.505 (0.92%)

CTWS

Connecticut Water

$66.09

0.34 (0.52%)

SJW

SJW Corp.

$67.82

1.31 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/19/18
06/19
14:17
06/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$146.84

-3.69 (-2.45%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Hot Stocks
Whirlpool drops further after AHAM data released »

Shares of Whirlpool have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYDY

CytoDyn

$0.00

(0.00%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities Association »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ZS

Zscaler

$37.56

-2.8 (-6.94%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Options
Zscaler Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

YPF

YPF

$16.57

0.35 (2.16%)

14:05
06/19/18
06/19
14:05
06/19/18
14:05
Options
YPF call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$67.79

-1.96 (-2.81%)

13:55
06/19/18
06/19
13:55
06/19/18
13:55
Options
Xilinx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.19

-0.215 (-0.73%)

13:49
06/19/18
06/19
13:49
06/19/18
13:49
Hot Stocks
Merrill Lynch to pay $42M penalty to settle SEC charges on trade 'masking' »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.54

-2.76 (-1.39%)

13:47
06/19/18
06/19
13:47
06/19/18
13:47
Hot Stocks
Facebook takes steps to make video more interactive »

Facebook shares updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

COTV

Cotiviti Holdings

$44.00

4.105 (10.29%)

13:43
06/19/18
06/19
13:43
06/19/18
13:43
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$140.20

34.72 (32.92%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

COTV

Cotiviti Holdings

$44.03

4.14 (10.38%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/19/18
06/19
13:40
06/19/18
13:40
Options
Alerian MLP attracts a large put buyer »

Alerian MLP attracts a…

FMBH

First Mid-Illinois Bancshares

$41.10

0.25 (0.61%)

13:39
06/19/18
06/19
13:39
06/19/18
13:39
Conference/Events
First Mid-Illinois Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 24

    Sep

STE

STERIS

$106.73

-0.82 (-0.76%)

13:37
06/19/18
06/19
13:37
06/19/18
13:37
Conference/Events
STERIS management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SRPT

Sarepta

$143.85

38.37 (36.38%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAIN

Hain Celestial

$29.55

0.69 (2.39%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Options
Hain Celestial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.38

0.175 (0.54%)

, VZ

Verizon

$48.54

1.08 (2.28%)

13:34
06/19/18
06/19
13:34
06/19/18
13:34
Periodicals
AT&T to end sale of user location data to third-party brokers, Verge reports »

AT&T (T) plans to end…

T

AT&T

$32.38

0.175 (0.54%)

VZ

Verizon

$48.54

1.08 (2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ORCL

Oracle

$46.18

-0.36 (-0.77%)

, MSFT

Microsoft

$100.35

-0.53 (-0.53%)

13:23
06/19/18
06/19
13:23
06/19/18
13:23
Earnings
On The Fly: What to watch for in Oracle's earnings report »

Oracle (ORCL) is…

ORCL

Oracle

$46.18

-0.36 (-0.77%)

MSFT

Microsoft

$100.35

-0.53 (-0.53%)

IBM

IBM

$143.49

-0.96 (-0.66%)

HPE

HP Enterprise

$15.78

-0.14 (-0.88%)

AMZN

Amazon.com

$1,712.48

-11.58 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

XLU

Utilities SPDR

$49.96

0.27 (0.54%)

13:20
06/19/18
06/19
13:20
06/19/18
13:20
Options
SPDR Repeat put buying in SPDR Utility ETF as the sector sees relative strength »

SPDR Repeat put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
06/19/18
06/19
13:20
06/19/18
13:20
General news
Treasury Action: so far there's no sign of a general boycott on Treasuries »

Treasury Action: so far…

SNAP

Snap

$12.95

-1.1 (-7.83%)

13:18
06/19/18
06/19
13:18
06/19/18
13:18
Periodicals
Snap adds to original programming with docu-series, Variety says »

According to Variety,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/19/18
06/19
13:17
06/19/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/19/18
06/19
13:16
06/19/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.